Skip to main content

Alzheimer’s Disease- Eli Lilly I8D-MC-AZET (DAYBREAK-ALZ)


The DAYBREAK-ALZ Study is a phase 3 clinical research study for people with memory problems or mild Alzheimer’s disease. The primary aim of the study is to slow down the decline in memory and mental functioning in patients with Alzheimer’s disease.

Sponsor: Eli Lilly and Company

Phase: 3

Indication: Have experienced a gradual loss of memory over the last 6 months or have been diagnosed with mild Alzheimer’s disease.

Age: 55 to 85 years of age

Category: Disease Modifying

For more information:


Studies Currently Available At

Sign Up For This Study